<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Danazol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Danazol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Danazol: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11715" href="/d/html/11715.html" rel="external">see "Danazol: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13199" href="/d/html/13199.html" rel="external">see "Danazol: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708691"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Thromboembolic events:</span>
<div class="collapsible-wrap">
<p style="text-indent:-4em;margin-left:4em;">Thromboembolism, thrombotic and thrombophlebitic events, including sagittal sinus thrombosis and life-threatening or fatal strokes have been reported.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pregnancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of danazol in pregnancy is contraindicated. A sensitive test (eg, beta subunit test if available) capable of determining early pregnancy is recommended immediately prior to start of therapy. Additionally, a nonhormonal method of contraception should be used during therapy. If a patient becomes pregnant while taking danazol, administration of the drug should be discontinued and the patient should be apprised of the potential risk to the fetus. Exposure to danazol in utero may result in androgenic effects on the female fetus; reports of clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been received.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Experience with long-term therapy with danazol is limited. Peliosis hepatis and benign hepatic adenoma have been observed with long-term use. Peliosis hepatis and hepatic adenoma may be silent until complicated by acute, potentially life-threatening intra-abdominal hemorrhage. The physician therefore should be alert to this possibility. Attempts should be made to determine the lowest dose that will provide adequate protection. If danazol was begun at a time of exacerbation of hereditary angioneurotic edema due to trauma, stress or other cause, periodic attempts to decrease or withdraw therapy should be considered.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Intracranial hypertension:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Danazol has been associated with several cases of benign intracranial hypertension also known as pseudotumor cerebri. Early signs and symptoms of benign intracranial hypertension include papilledema, headache, nausea and vomiting, and visual disturbances. Patients with these symptoms should be screened for papilledema and, if present, the patients should be advised to discontinue danazol immediately and be referred to a neurologist for further diagnosis and care.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866506"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cyclomen</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F156678"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Androgen</li></ul></div>
<div class="block doa drugH1Div" id="F156640"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46c9c161-3a00-43b9-b6a4-9d35ba3a22b8">Endometriosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometriosis (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use as an alternative to other first-line therapies in patients with pain associated with endometriosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20567196']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20567196'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mild disease:</i>
<b>Oral:</b> 200 to 400 mg/day in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Moderate to severe disease or infertility due to endometriosis:</i>
<b>Oral:</b> 800 mg/day in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment:</b> Gradually reduce dosage to maintain amenorrhea.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy:</b> Continue therapy uninterrupted for 3 to 6 months; may extend up to 9 months, if needed. If symptoms recur following discontinuation, may reinitiate treatment.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="858f019b-e710-46a8-92c9-43880949c068">Fanconi anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fanconi anemia (alternative agent) (off-label use): Oral: </b>Initial: ~3 to 7.7 mg/kg/day; if response observed, may gradually taper dose to ~65% of original dose after ~2 years, and further taper to ~54% after another year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sroka.2020','lexi-content-ref-22178060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sroka.2020','lexi-content-ref-22178060'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a39710ed-d7c6-4808-9b5f-163ad50ecca1">Hereditary angioedema, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema, prophylaxis (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be considered as an alternative to other first-line therapies for preprocedural (short-term) and long-term hereditary angioedema (HAE) attack prophylaxis. Danazol is <b>not</b> recommended for treatment of acute HAE attacks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35497649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35497649'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Preprocedural (short-term) prophylaxis (off-label dose): <b>Oral:</b> 400 to 600 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32898710','lexi-content-ref-23282420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32898710','lexi-content-ref-23282420'])">Ref</a></span>). Administer for 5 days before and for 2 to 3 days after procedure; frequent short courses may lead to adverse effects associated with long-term use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35497649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35497649'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Long-term prophylaxis: <b>Oral:</b> Initial: 100 to 200 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23282420','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23282420','lexi-content-ref-Manu.1'])">Ref</a></span>). After favorable initial response, decrease the dosage by 50% or less at intervals of 1 to 3 months or longer if the frequency of attacks dictates; if an attack occurs, increase the daily dosage by up to 200 mg/day. Usual dosage range: 100 mg every other day to 200 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35497649','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35497649','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Use the minimum effective dose; use of dosages &gt;200 mg/day for an extended time is not recommended due to adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35497649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35497649'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9595f85a-cac8-40ea-96d1-e65268033fa1">Immune thrombocytopenia, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune thrombocytopenia, refractory (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be considered in patients whose symptoms are refractory to or who are unable to take other preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31794604','lexi-content-ref-31770441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31794604','lexi-content-ref-31770441'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 200 mg 2 to 4 times/day; approximate time to response is 3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31770441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31770441'])">Ref</a></span>) <b>or</b> 600 mg once daily for at least 6 months followed by 400 mg once daily for 3 months, then (if remission maintained) 200 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15093754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15093754'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6ffa7e9c-beb1-49f2-bcd1-041646066eed">Mastalgia, cyclic, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mastalgia, cyclic, severe (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use in patients with severe or refractory cyclic breast pain associated with benign breast disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27214189']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27214189'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 200 mg/day administered in 1 or 2 divided doses. Cyclic administration during the luteal phase of the menstrual cycle (days 14 to 28) may reduce the risk of adverse effects; if given continuously, initiate the first day of the menstrual cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27214189','lexi-content-ref-9914571']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27214189','lexi-content-ref-9914571'])">Ref</a></span>). Usual dosage range: 100 to 200 mg/day; doses up to 400 mg/day have been studied but may be associated with a higher incidence of adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27214189','lexi-content-ref-6388218','lexi-content-ref-3527249','lexi-content-ref-9476088','lexi-content-ref-6122770','lexi-content-ref-6594009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27214189','lexi-content-ref-6388218','lexi-content-ref-3527249','lexi-content-ref-9476088','lexi-content-ref-6122770','lexi-content-ref-6594009'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration of therapy: </i>3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27214189']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27214189'])">Ref</a></span>). In some studies in patients receiving continuous (ie, not cyclic) therapy, the dose was tapered off prior to discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27214189','lexi-content-ref-6388218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27214189','lexi-content-ref-6388218'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990071"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use is contraindicated in patients with markedly impaired renal function.</p></div>
<div class="block doha drugH1Div" id="F50987355"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use is contraindicated in patients with markedly impaired hepatic function.</p></div>
<div class="block doe drugH1Div" id="F156641"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F52812500"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13199" href="/d/html/13199.html" rel="external">see "Danazol: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a39710ed-d7c6-4808-9b5f-163ad50ecca1">Hereditary angioedema, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema, prophylaxis (alternate agent): </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Short-term prophylaxis (for patient-specific triggers, medical and dental procedures)</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For planned procedures, on-demand therapy with C1-inhibitor concentrate is preferred; however, if not available, danazol may be considered if time allows adequate therapy before procedure or if patient uses danazol as long-term prophylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27503784','lexi-content-ref-29318628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27503784','lexi-content-ref-29318628'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Postpubescent Children and Adolescents: Oral: 2.5 to 10 mg/kg/day divided into 3 doses; maximum daily dose: 600 mg/<b>day</b>; begin at least 5 to 7 days prior and continue for 2 to 5 days post-procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27503784','lexi-content-ref-24565617','lexi-content-ref-32898710','lexi-content-ref-23282420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27503784','lexi-content-ref-24565617','lexi-content-ref-32898710','lexi-content-ref-23282420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Long-term prophylaxis</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Use is not recommended in children due to potential adverse effects on bone, growth, and sexual development (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32898710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32898710'])">Ref</a></span>). Danazol is not a preferred first-line agent; use should be reserved for situations when C1-inhibitor concentrate (first-line) are not available or patient preference for oral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32898710','lexi-content-ref-29318628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32898710','lexi-content-ref-29318628'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≥16 years: Oral: Initial: 2.5 mg/kg/day; maximum initial daily dose: 50 mg/<b>day</b>; increase slowly every 2 weeks until symptoms controlled, or maximum tolerated or maximum recommended dose is reached; maximum daily dose: 5 mg/kg/<b>day</b> up to 200 mg/<b>day</b>. Once control is obtained, reduce interval to every other day or every third day; maximum dose: 100 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27503784','lexi-content-ref-32898710','lexi-content-ref-23282420','lexi-content-ref-29318628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27503784','lexi-content-ref-32898710','lexi-content-ref-23282420','lexi-content-ref-29318628'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729684"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Use is contraindicated in patients with markedly impaired renal function.</p></div>
<div class="block dohp drugH1Div" id="F52729685"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Use is contraindicated in patients with markedly impaired hepatic function.</p></div>
<div class="block adr drugH1Div" id="F156607"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Boos 2003), edema, flushing, increased blood pressure, palpitations, syncope, tachycardia, thrombosis (including thromboembolic complications and thromboembolism [cerebrovascular accident, sagittal sinus thrombosis]) (Alvarado 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, alopecia (Duff 1981), diaphoresis, erythema multiforme (Reynolds 1992), maculopapular rash, papular rash, pruritus, purpuric rash, seborrhea, skin photosensitivity, Stevens-Johnson syndrome (Koh 2015), urticaria, vesicular eruption</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Altered serum glucose (including abnormal glucose tolerance test) (Williams 1985), change in libido, changes in serum lipids (including decreased HDL cholesterol and increased LDL cholesterol) (Luciano 1983), decreased sex hormone binding globulin (Forbes 1986), decreased thyroxine binding globulin, exacerbation of porphyria (Lamon 1979), fluid retention, hirsutism (Zawar 2004), increased sex hormone-binding globulin, increased thyroxine binding globulin, menstrual disease (amenorrhea, irregular menses, spotty menstruation), weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Change in appetite, constipation, gastroenteritis, gingival hemorrhage, nausea, pancreatitis (Balasch 1994), vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast atrophy, clitoromegaly, decreased ejaculate volume, hematuria, inhibition of spermatogenesis, nipple discharge, pelvic pain, spermatozoa disorder (including changes in asthenospermia, semen viscosity, and sperm count), vaginal dryness, vaginal irritation</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Abnormal erythrocytes (increased) (Barton 1987), change in serum protein, eosinophilia, leukocytosis, leukopenia, petechial rash, polycythemia, purpuric disease (splenic peliosis) (Arai 2007), thrombocythemia, thrombocytopenia (Yamamoto 1997)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic adenoma (Middleton 1989), hepatic failure (Hayashi 2001), hepatic neoplasm (malignant; after prolonged use; hepatocellular neoplasm) (Berkel 2014), hepatotoxicity (idiosyncratic) (Chalasani 2014), increased liver enzymes, jaundice (including cholestatic jaundice and hepatocellular jaundice) (Qaseem 1992), peliosis hepatitis (Makdisi 1995)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, asthenia, chills, depression, dizziness, emotional lability, fatigue, Guillain-Barre syndrome (Hory 1985), headache, intracranial hypertension (Tan 2019), nervousness, paresthesia, seizure, sleep disorder, voice disorder (deepening of the voice, hoarseness, instability, sore throat), tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, back pain, increased creatine phosphokinase in blood specimen, joint swelling, limb pain, muscle cramps, muscle spasm, myalgia, neck pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pneumonitis, nasal congestion</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F156619"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to danazol or any component of the formulation; undiagnosed abnormal genital bleeding; pregnancy; breastfeeding; porphyria; markedly impaired hepatic, renal, or cardiac function; androgen-dependent tumor; active or history of thrombosis or thromboembolic disease</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Genital neoplasia; concomitant administration with simvastatin.</p></div>
<div class="block war drugH1Div" id="F156604"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Androgenic effects: May cause nonreversible androgenic effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Blood lipid changes: Anabolic steroids may cause blood lipid changes (decreased high density lipoproteins and increased low density lipoproteins) with increased risk of arteriosclerosis and coronary artery disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cyclic breast pain (mastalgia) associated with benign breast disorders: Use is reserved for severe and refractory cases that have not responded to conservative measures and analgesics. Malignancy should be ruled out prior to therapy (ACOG 2016; Groen 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; insulin requirements may be increased; monitor carefully.</p>
<p style="text-indent:-2em;margin-left:4em;">• Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); danazol may cause fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: May cause exacerbations of acute intermittent porphyria; use is contraindicated in patients with porphyria.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Endometriosis: Danazol is generally reserved for the treatment of pain associated with endometriosis when other agents are not available, due to its high incidence of adverse events (Dunselman 2014).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878406"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Due to irreversible androgenic side effects, danazol should be avoided in prepubescent pediatric patients and exposure in adolescents should be limited; in adolescents, assess risk versus benefit; monitor patients closely (Laufer 2008; US HAEA [Busse 2021]; WAO [Craig 2012]; Zuraw 2013b).</p></div>
<div class="block foc drugH1Div" id="F156615"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg, 200 mg</p></div>
<div class="block geq drugH1Div" id="F156600"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F156621"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Danazol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $3.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $5.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $10.29 - $12.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866507"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cyclomen: 50 mg, 100 mg, 200 mg</p></div>
<div class="block adm drugH1Div" id="F14259298"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Endometriosis: Initiate therapy during menstruation or ensure patient is not pregnant while on therapy.</p></div>
<div class="block admp drugH1Div" id="F52612481"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer consistently with regard to food.</p></div>
<div class="block use drugH1Div" id="F156616"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometriosis: </b>Treatment of endometriosis amenable to hormonal management.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema, prophylaxis:</b> Prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal).</p></div>
<div class="block off-label drugH1Div" id="F25942024"><span class="drugH1">Use: Off-Label: Adult</span><p>Fanconi anemia (alternative agent); Immune thrombocytopenia, refractory; Mastalgia, cyclic, severe</p></div>
<div class="block mst drugH1Div" id="F156684"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Danazol may be confused with Dantrium</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F156674"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Inhibits</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F156608"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Androgens may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: Danazol may increase the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">C1 inhibitors: Androgens may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the fluid-retaining effect of Androgens.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).  Management: Consider avoiding concomitant use of androgens and cyclosporine. If concomitant use is unavoidable, monitor serum cyclosporine concentrations and for signs and symptoms of hepatotoxicity. Cyclosporine dose reductions may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypertension-Associated Agents: May enhance the hypertensive effect of Androgens.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib.  Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: Danazol may increase the serum concentration of Lovastatin.  Management: Initiate immediate release lovastatin at a dose of 10 mg/day, and do not exceed 20 mg/day for immediate or extended release lovastatin, in patients receiving danazol. Monitor closely for signs of lovastatin toxicity (eg, myositis, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: Danazol may increase the serum concentration of Red Yeast Rice.  Management: Initiate red yeast rice at a dose equivalent to lovastatin 10 mg/day, and do not exceed 20 mg/day, in patients receiving danazol. Monitor closely for signs of lovastatin toxicity (eg, myositis, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: Danazol may increase the serum concentration of Simvastatin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: Danazol may enhance the hypercalcemic effect of Vitamin D Analogs. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Monitor for increased effects of vitamin K antagonists if an androgen is initiated/dose increased, or decreased effects if androgen is discontinued/dose decreased. Significant reductions in vitamin K antagonist dose are likely required.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F156630"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food delays time to peak levels. A high-fat meal increases plasma concentration and extent of availability.</p></div>
<div class="block rep_considerations drugH1Div" id="F49297587"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who may become pregnant. A sensitive test capable of determining early pregnancy is recommended immediately prior to start of therapy (eg, beta subunit test, if available). A nonhormonal method of contraception should be used during therapy.</p>
<p style="text-indent:0em;margin-top:2em;">Menstrual disturbances may occur during therapy. Although ovulation may return within 60 to 90 days once danazol is discontinued, persistent amenorrhea may occur. Spermatogenesis and abnormalities in semen volume, viscosity, count, and motility may occur with long-term therapy.</p></div>
<div class="block pri drugH1Div" id="F156622"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Androgens cross the placenta (US HAEA [Busse 2021]; WAO/EAACI [Maurer 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Exposure to danazol in utero may result in androgenic effects on the female fetus; reports of clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been received.</p>
<p style="text-indent:0em;margin-top:2em;">Use of danazol in pregnancy is contraindicated. If a patient becomes pregnant while taking danazol, administration of the drug should be discontinued, and the patient should be apprised of the potential risk to the fetus.</p>
<p style="text-indent:0em;margin-top:2em;">The use of danazol for the management of hereditary angioedema (HAE) in pregnancy that is not responsive to preferred therapy has been described in case reports (Altman 2006; Boulos 1994; González-Quevedo 2016; Milingos 2009). However, danazol is contraindicated during pregnancy; current guidelines recommend use of agents other than danazol to treat HAE in pregnant patients. Patients with HAE should be monitored closely during pregnancy and for at least 72 hours after delivery (WAO/EAACI [Maurer 2022]).</p></div>
<div class="block brc drugH1Div" id="F20305959"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Androgens are present in breast milk (US HAEA [Busse 2021]; WAO/EAACI [Maurer 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">Use of danazol is contraindicated in breastfeeding patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Lactation may increase the frequency of hereditary angioedema (HAE) attacks; patients with HAE should be monitored closely. Current hereditary angioedema guidelines recommend use of other agents in breastfeeding patients; breastfeeding should be discontinued prior to starting therapy with danazol (WAO/EAACI [Maurer 2022]).</p></div>
<div class="block mop drugH1Div" id="F156613"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Liver and renal function tests (periodically); hematologic parameters; lipid panel. Signs and symptoms of intracranial hypertension (papilledema, headache, nausea, vomiting), androgenic changes, and/or fluid retention. Evaluate pregnancy status prior to use in patients who may become pregnant.</p>
<p style="text-indent:-2em;margin-left:2em;">Hereditary angioedema, long-term prophylaxis: CBC, urinalysis, liver function test and lipid profile (baseline, every 6 months while on therapy and 6 months after discontinuation); liver ultrasound (baseline and annually); blood pressure (every 6 months) (WAO [Craig 2012])</p>
<p style="text-indent:-2em;margin-left:2em;">Cyclic breast pain (mastalgia) associated with benign breast disorders: Pain and side effects; in most studies this was done (at a minimum) following 1, 3, and 6 months of therapy (Döberl 1984; Hinton 1986; Kontostolis 1997; Mansel 1982; Tobiassen 1984)</p></div>
<div class="block pha drugH1Div" id="F156603"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Suppresses pituitary output of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), resulting in regression and atrophy of normal and ectopic endometrial tissue; decreases rate of growth of abnormal breast tissue; reduces attacks associated with hereditary angioedema by increasing levels of C4 component of complement </p></div>
<div class="block phk drugH1Div" id="F156618"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Immune thrombocytopenia (off-label use): Initial response: 14 to 90 days; Peak response: 28 to 180 days (Neunert 2011)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic, primarily to 2-hydroxymethyl danazol and ethisterone</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 9.7 ± 3.29 hours (variable; up to 24 hours following long-term use for endometriosis)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 4 hours (range: 2 to 8 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine and feces</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F156623"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Danocrine | Danol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ladogal</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Danokrin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Azol | Danocrine</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Danamet | Danodiol | Danzol | Gonablok | Lozana</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Danatrol</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Danoval</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ladogal</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Danatrol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Danogar</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cipladanogen | Danagin | Ladogal</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Anargil | Danatrol | Danol | Danoval</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Danazol-ratiopharm | Winobanin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ladogal</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Danodiol | Ladogal</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Danatrol | Danol</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Danol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Danatrol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Danatrol | Danocrine</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Danatrol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Danazol cox | Danazol kent | Danazol sterwin | Danol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Danatrol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Anargil | Danocrine | Ectopal</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Danoval</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Danoval</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Azol | Danocrene | Danocrine</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Danatrol | Danol</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Danocrine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Danogen | Danozec | Endometryl | Gonablok | Gynadom | Gynazol | Gynodan | Gynol | Ladogal | Zendol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Danatrol</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Danol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Anason | Anason choseido | Baxal | Belrinat | Bonzol | Dainazol | Danan | Danazol maruko | Danazol Nichiiko | Danazolen | Danazorik | Danazorik choseido | Esdelart | Hosebon | Oyslon | Sofunarin | Them</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Danocil | Danocrin | Danocrine | Danzocurine | Unidana | Youngpoong danazol</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Danol</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Danocrine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Danogen | Danol | Danoval | Danozolis</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Danatrol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Danatrol | Danogen | Danol | Danoval</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Danatrol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Danalem | Ladogal</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Anargil | Azol | Danzol | Duozol | Ladogal | Nazol | Vabon</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Danal</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Danatrol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Danatrol | Danazol-ratiopharm | Danocrine | Danol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Azol | Cyclomen | D-Zol | Danatrol | Danocrine</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ladogal</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ladogal</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Danatris | Danaxy | Danocrine | Danzol | Depest</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Danol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Danocrine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Danatrol | Danol | Mastodanatrol</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Danol</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Danol | Danoval</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Danogen | Danol | Danoval</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Danol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Azol | Ladogal</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Danoval</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Anargil | Danol | Danoval</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Anargil | Danodiol | Ectopal | Ladogal | Vabon</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Danatrol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Danasin | Danatrol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cyclolady | Danal | Danalol | Danodiol | Danol | Danonice | Dorink | Ectopal | Kodazol | Ladogal | Lazol | Syntozal | Unazol</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Danol | Danoval</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ladogal</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ladogal</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Kupdina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Danogen | Ladazol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11743571">
<a name="11743571"></a>Alvarado RG, Liu JY, Zwolak RM. Danazol and limb-threatening arterial thrombosis: two case reports. <i>J Vasc Surg</i>. 2001;34(6):1123-1126. doi:10.1067/mva.2001.118078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/11743571/pubmed" id="11743571" target="_blank">11743571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20567196">
<a name="20567196"></a>American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology (ACOG). Practice Bulletin No. 114: Management of endometriosis. <i>Obstet Gynecol</i>. 2010;116(1):223-236. doi:10.1097/AOG.0b013e3181e8b073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/20567196/pubmed" id="20567196" target="_blank">20567196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27214189">
<a name="27214189"></a>American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology (ACOG). Practice Bulletin No. 164: Diagnosis and Management of Benign Breast Disorders. <i>Obstet Gynecol</i>. 2016;127(6):e141-e156. doi: 10.1097/AOG.0000000000001482.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/27214189/pubmed" id="27214189" target="_blank">27214189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18055339">
<a name="18055339"></a>Arai S, Asai T, Uozaki H, et al. Splenic peliosis in a patient with aplastic anemia during danazol therapy. <i>Int J Hematol</i>. 2007;86(4):329-332. doi:10.1532/IJH97.07078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/18055339/pubmed" id="18055339" target="_blank">18055339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7962394">
<a name="7962394"></a>Balasch J, Martinez-Román S, Carreras J, Vanrell JA. Acute pancreatitis associated with danazol treatment for endometriosis. <i>Hum Reprod</i>. 1994;9(6):1163-1165. doi:10.1093/oxfordjournals.humrep.a138651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/7962394/pubmed" id="7962394" target="_blank">7962394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3103832">
<a name="3103832"></a>Barton IK, Mansell MA. Erythrocytosis induced by danazol in an anephric patient. <i>Br Med J (Clin Res Ed)</i>. 1987;294(6572):615. doi:10.1136/bmj.294.6572.615<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/3103832/pubmed" id="3103832" target="_blank">3103832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12918508">
<a name="12918508"></a>Boos CJ, Dawes M, Jones R, Farrell T. Danazol treatment and acute myocardial infarction. <i>J Obstet Gynaecol</i>. 2003;23(3):327-328. doi:10.1080/01443610310000106064<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/12918508/pubmed" id="12918508" target="_blank">12918508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32898710">
<a name="32898710"></a>Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. <i>J Allergy Clin Immunol Pract</i>. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/32898710/pubmed" id="32898710" target="_blank">32898710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22197274">
<a name="22197274"></a>Caballero T, Farkas H, Bouillet L, et al, "International Consensus and Practical Guidelines on the Gynecologic and Obstetric Management of Female Patients With Hereditary Angioedema Caused by C1 Inhibitor Deficiency," <i>J Allergy Clin Immunol</i>, 2012, 129(2):308-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/22197274/pubmed" id="22197274" target="_blank">22197274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23282420">
<a name="23282420"></a>Craig T, Aygören-Pürsün E, Bork K, et al. WAO guideline for the management of hereditary angioedema. <i>World Allergy Organ J</i>. 2012;5(12):182-199. doi: 10.1097/WOX.0b013e318279affa.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/23282420/pubmed" id="23282420" target="_blank">23282420</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cyclomen (danazol) [product monograph]. Laval, Quebec, Canada: Sanofi-aventis Canada Inc.; May 2017.</div>
</li>
<li>
<div class="reference">
                  Danazol [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc; April 2018.</div>
</li>
<li>
<div class="reference">
                  Danazol [prescribing information]. Philadelphia, PA: Lannett Company; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18848179">
<a name="18848179"></a>Daou S, Federici L, Zimmer J, Maloisel F, Serraj K, Andrès E. Idiopathic thrombocytopenic purpura in elderly patients: a study of 47 cases from a single reference center. <i>Eur J Intern Med</i>. 2008;19(6):447-451.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/18848179/pubmed" id="18848179" target="_blank">18848179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6388218">
<a name="6388218"></a>Döberl A, Tobiassen T, Rasmussen T. Treatment of recurrent cyclical mastodynia in patients with fibrocystic breast disease. A double-blind placebo-controlled study—the Hjørring project. <i>Acta Obstet Gynecol Scand Suppl</i>. 1984;123:177-184.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/6388218/pubmed" id="6388218" target="_blank">6388218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7282815">
<a name="7282815"></a>Duff P, Mayer AR. Generalized alopecia: an unusual complication of danazol therapy. <i>Am J Obstet Gynecol</i>. 1981;141(3):349-350. doi:10.1016/s0002-9378(16)32645-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/7282815/pubmed" id="7282815" target="_blank">7282815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24435778">
<a name="24435778"></a>Dunselman GA, Vermeulen N, Becker C, et al; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. <i>Hum Reprod</i>. 2014;29(3):400-412. doi:10.1093/humrep/det457.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/24435778/pubmed" id="24435778" target="_blank">24435778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27503784">
<a name="27503784"></a>Farkas H, Martinez-Saguer I, Bork K, et al; HAWK. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. <i>Allergy</i>. 2017;72(2):300-313. doi: 10.1111/all.13001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/27503784/pubmed" id="27503784" target="_blank">27503784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3304725">
<a name="3304725"></a>Forbes KL, Dowsett M, Rose GL, Mudge JE, Jeffcoate SL. Dosage-related effects of danazol on sex hormone binding globulin and free and total androgen levels. <i>Clin Endocrinol (Oxf)</i>. 1986;25(5):597-605. doi:10.1111/j.1365-2265.1986.tb03614.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/3304725/pubmed" id="3304725" target="_blank">3304725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27326983">
<a name="27326983"></a>González-Quevedo T, Larco JI, Marcos C, et al. Management of pregnancy and delivery in patients with hereditary angioedema due to C1 inhibitor deficiency. <i>J Investig Allergol Clin Immunol</i>. 2016;26(3):161-167. doi: 10.18176/jiaci.0037.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/27326983/pubmed" id="27326983" target="_blank">27326983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29059585">
<a name="29059585"></a>Groen JW, Grosfeld S, Bramer WM, Ernst MF, Mullender MM. Cyclic and non-cyclic breast-pain: A systematic review on pain reduction, side effects, and quality of life for various treatments. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2017;219:74-93. doi: 10.1016/j.ejogrb.2017.10.018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/29059585/pubmed" id="29059585" target="_blank">29059585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11757752">
<a name="11757752"></a>Hayashi T, Takahashi T, Minami T, et al. Fatal acute hepatic failure induced by danazol in a patient with endometriosis and aplastic anemia. <i>J Gastroenterol</i>. 2001;36(11):783-786. doi:10.1007/s005350170022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/11757752/pubmed" id="11757752" target="_blank">11757752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3527249">
<a name="3527249"></a>Hinton CP, Bishop HM, Holliday HW, Doyle PJ, Blamey RW. A double-blind controlled trial of danazol and bromocriptine in the management of severe cyclical breast pain. <i>Br J Clin Pract</i>. 1986;40(8):326-330.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/3527249/pubmed" id="3527249" target="_blank">3527249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4014294">
<a name="4014294"></a>Hory B, Blanc D, Boillot A, Panouse-Perrin J. Guillain-Barré syndrome following danazol and corticosteroid therapy for hereditary angioedema. <i>Am J Med</i>. 1985;79(1):111-114. doi:10.1016/0002-9343(85)90553-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/4014294/pubmed" id="4014294" target="_blank">4014294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20478287">
<a name="20478287"></a>Kishino Y, Tanaka Y, Naitoh S, et al, "Danazol Falsely Increased Values in Estradiol Immunoassays," <i>Clin Chim Acta</i>, 2010, 411(17-18):1380-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/20478287/pubmed" id="20478287" target="_blank">20478287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25612133">
<a name="25612133"></a>Koh WL, Tay YK, Koh MJ. Danazol-induced Stevens-Johnson syndrome in a patient with systemic lupus erythematosus. <i>Dermatol Online J</i>. 2015;21(1):13030/qt24v513b9. Published 2015 Jan 15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/25612133/pubmed" id="25612133" target="_blank">25612133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9476088">
<a name="9476088"></a>Kontostolis E, Stefanidis K, Navrozoglou I, Lolis D. Comparison of tamoxifen with danazol for treatment of cyclical mastalgia. <i>Gynecol Endocrinol</i>. 1997;11(6):393-397.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/9476088/pubmed" id="9476088" target="_blank">9476088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-422693">
<a name="422693"></a>Lamon JM, Frykholm BC, Herrera W, Tschudy DP. Danazol administration to females with menses-associated exacerbations of acute intermittent porphyria. <i>J Clin Endocrinol Metab</i>. 1979;48(1):123-126. doi:10.1210/jcem-48-1-123<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/422693/pubmed" id="422693" target="_blank">422693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18936548">
<a name="18936548"></a>Laufer MR. Current approaches to optimizing the treatment of endometriosis in adolescents. <i>Gynecol Obstet Invest</i>. 2008;66(Suppl 1):S19-S27. doi:10.1159/000148027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/18936548/pubmed" id="18936548" target="_blank">18936548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26681745">
<a name="26681745"></a>Liu W, Gu X, Fu R, et al. The effect of danazol in primary immune thrombocytopenia: an analysis of a large cohort from a single center in China. <i>Clin Appl Thromb Hemost</i>. 2016;22(8):727-733.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/26681745/pubmed" id="26681745" target="_blank">26681745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6824034">
<a name="6824034"></a>Luciano AA, Hauser KS, Chapler FK, Davis WA, Wallace RB. Effects of danazol on plasma lipid and lipoprotein levels in healthy women and in women with endometriosis. <i>Am J Obstet Gynecol</i>. 1983;145(4):422-426. doi:10.1016/0002-9378(83)90311-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/6824034/pubmed" id="6824034" target="_blank">6824034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7847311">
<a name="7847311"></a>Makdisi WJ, Cherian R, Vanveldhuizen PJ, Talley RL, Stark SP, Dixon AY. Fatal peliosis of the liver and spleen in a patient with agnogenic myeloid metaplasia treated with danazol. <i>Am J Gastroenterol</i>. 1995;90(2):317-318.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/7847311/pubmed" id="7847311" target="_blank">7847311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15093754">
<a name="15093754"></a>Maloisel F, Andrès E, Zimmer J, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. <i>Am J Med.</i> 2004;116(9):590-594.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/15093754/pubmed" id="15093754" target="_blank">15093754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6122770">
<a name="6122770"></a>Mansel RE, Wisbey JR, Hughes LE. Controlled trial of the antigonadotropin danazol in painful nodular benign breast disease. <i>Lancet</i>. 1982;1(8278):928-930.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/6122770/pubmed" id="6122770" target="_blank">6122770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29318628">
<a name="29318628"></a>Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema: the 2017 revision and update. <i>Allergy</i>. 2018;73(8):1575-1596. doi: 10.1111/all.13384.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/29318628/pubmed" id="29318628" target="_blank">29318628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35497649">
<a name="35497649"></a>Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema - the 2021 revision and update.<i> World Allergy Organ J</i>. 2022;15(3):100627. doi:10.1016/j.waojou.2022.100627<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/35497649/pubmed" id="35497649" target="_blank">35497649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2561047">
<a name="2561047"></a>Middleton C, McCaughan GW, Painter DM, Stephen MS, Beale M, Fraser I. Danazol and hepatic neoplasia: a case report. <i>Aust N Z J Med</i>. 1989;19(6):733-735. doi:10.1111/j.1445-5994.1989.tb00350.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/2561047/pubmed" id="2561047" target="_blank">2561047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27582827">
<a name="27582827"></a>Milingos DS, Madhuvrata P, Dean J, et al. Hereditary angioedema and pregnancy: successful management of recurrent and frequent attacks of angioedema with C1-inhibitor concentrate, danazol and tranexamic acid - a case report. <i>Obstet Med</i>. 2009;2(3):123-125. doi: 10.1258/om.2009.090003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/27582827/pubmed" id="27582827" target="_blank">27582827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21325604">
<a name="21325604"></a>Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. <i>Blood.</i> 2011;117(16):4190-4207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/21325604/pubmed" id="21325604" target="_blank">21325604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31794604">
<a name="31794604"></a>Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. <i>Blood Adv</i>. 2019;3(23):3829-3866. doi:10.1182/bloodadvances.2019000966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/31794604/pubmed" id="31794604" target="_blank">31794604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9914571">
<a name="9914571"></a>O'Brien PM, Abukhalil IE. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. <i>Am J Obstet Gynecol</i>. 1999;180(1, pt 1):18-23. doi:10.1016/s0002-9378(99)70142-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/9914571/pubmed" id="9914571" target="_blank">9914571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31770441">
<a name="31770441"></a>Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Adv</i>. 2019;3(22):3780-3817. doi:10.1182/bloodadvances.2019000812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/31770441/pubmed" id="31770441" target="_blank">31770441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1494534">
<a name="1494534"></a>Qaseem T, Jafri W, Khurshid M, Khan H. Cholestatic jaundice associated with danazol therapy. <i>Postgrad Med J</i>. 1992;68(806):984-985. doi:10.1136/pgmj.68.806.984-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/1494534/pubmed" id="1494534" target="_blank">1494534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1387593">
<a name="1387593"></a>Reynolds NJ, Sansom JE. Erythema multiforme during danazol therapy. <i>Clin Exp Dermatol</i>. 1992;17(2):140. doi:10.1111/j.1365-2230.1992.tb00184.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/1387593/pubmed" id="1387593" target="_blank">1387593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22178060">
<a name="22178060"></a>Scheckenbach K, Morgan M, Filger-Brillinger J, et al. Treatment of the bone marrow failure in Fanconi anemia patients with danazol. <i>Blood Cells Mol Dis</i>. 2012;48(2):128-131. doi:10.1016/j.bcmd.2011.11.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/22178060/pubmed" id="22178060" target="_blank">22178060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sroka.2020">
<a name="Sroka.2020"></a>Sroka I, Frohnmayer L, Van Ravenhorst S, et al, eds. Fanconi anemia clinical care guidelines. 5th edition. Fanconi Anemia Research Fund; 2020. https://www.fanconi.org/images/uploads/other/Fanconi_Anemia_Clinical_Care_Guidelines_5thEdition_web.pdf. Accessed February 18, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31741184">
<a name="31741184"></a>Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes [published online November 18, 2019]. <i>Am J Clin Dermatol</i>. 2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/31741184/pubmed" id="31741184" target="_blank">31741184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6594009">
<a name="6594009"></a>Tobiassen T, Rasmussen T, Döberl A, Rannevik G. Danazol treatment of severely symptomatic fibrocystic breast disease and long-term follow-up—the Hjørring project. <i>Acta Obstet Gynecol Scand Suppl</i>. 1984;123:159-176. doi:10.3109/00016348409157006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/6594009/pubmed" id="6594009" target="_blank">6594009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14734334">
<a name="14734334"></a>Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. <i>Ann Intern Med</i>. 2004;140(2):112-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/14734334/pubmed" id="14734334" target="_blank">14734334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3931833">
<a name="3931833"></a>Williams G, Lofts F, Fuessl H, Bloom S. Treatment with danazol and plasma glucagon concentration. <i>Br Med J (Clin Res Ed)</i>. 1985;291(6503):1155-1156. doi:10.1136/bmj.291.6503.1155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/3931833/pubmed" id="3931833" target="_blank">3931833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9362107">
<a name="9362107"></a>Yamamoto K, Hoshiai H, Tsubaki K, Kasano Y, Shimizu K, Horiuchi A. Danazol induced thrombocytopenia. <i>Tohoku J Exp Med</i>. 1997;182(3):249-252. doi:10.1620/tjem.182.249<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/9362107/pubmed" id="9362107" target="_blank">9362107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15605967">
<a name="15605967"></a>Zawar V, Sankalecha C. Facial hirsutism following danazol therapy. <i>Cutis</i>. 2004;74(5):301-303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/15605967/pubmed" id="15605967" target="_blank">15605967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15053808">
<a name="15053808"></a>Zimmer J, Andres E, Noel E, Koumarianou A, Blickle JF, Maloisel F. Current management of adult idiopathic thrombocytopenic purpura in practice: a cohort study of 201 patients from a single center. <i>Clin Lab Haem</i>. 2004;26(2):137-142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/15053808/pubmed" id="15053808" target="_blank">15053808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24565617">
<a name="24565617"></a>Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. <i>J Allergy Clin Immunol Pract</i>. 2013a;1(5):458-467.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/24565617/pubmed" id="24565617" target="_blank">24565617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23726531">
<a name="23726531"></a>Zuraw BL, Bernstein JA, Lang DM, et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. <i>J Allergy Clin Immunol</i>. 2013b;131(6):1491-1493.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danazol-drug-information/abstract-text/23726531/pubmed" id="23726531" target="_blank">23726531</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9321 Version 221.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
